OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Neurology is 61. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?	1637
Technology of deep brain stimulation: current status and future directions	477
Recovery from disorders of consciousness: mechanisms, prognosis and emerging therapies	365
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	335
Maternal immune activation and neuroinflammation in human neurodevelopmental disorders	309
Diagnosis and management of migraine in ten steps	275
Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease	225
Prodromal Parkinson disease subtypes — key to understanding heterogeneity	213
Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus	205
Developing the ATX(N) classification for use across the Alzheimer disease continuum	183
Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits	182
Cycles in epilepsy	173
Synaptic degeneration in Alzheimer disease	172
Improving clinical trial outcomes in amyotrophic lateral sclerosis	170
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic	161
Advances in local therapy for glioblastoma — taking the fight to the tumour	159
Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration	155
Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours	149
Neurological infection with SARS-CoV-2 — the story so far	148
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility	146
B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies	143
The effects of the COVID-19 pandemic on people with dementia	141
The human connectome in Alzheimer disease — relationship to biomarkers and genetics	135
Stroke in Africa: profile, progress, prospects and priorities	131
Circadian rhythms in neurodegenerative disorders	124

Global epidemiology of migraine and its implications for public health and health policy	123
The inter-relationship between delirium and dementia: the importance of delirium prevention	115
Human cerebral organoids — a new tool for clinical neurology research	112
The metabolic basis of epilepsy	108
Apparent changes in the epidemiology and severity of multiple sclerosis	107
Single-cell and spatial transcriptomics: deciphering brain complexity in health and disease	98
Psychosis in Alzheimer disease — mechanisms, genetics and therapeutic opportunities	97
Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis	97
The neuroanatomical–functional paradox in spinal cord injury	96
Non-neuronal cells in amyotrophic lateral sclerosis — from pathogenesis to biomarkers	96
Hypomyelinating leukodystrophies — unravelling myelin biology	95
Pharmacological brain cytoprotection in acute ischaemic stroke — renewed hope in the reperfusion era	92
The importance of ongoing international surveillance for Creutzfeldt–Jakob disease	91
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease	89
Gene–environment interactions in Alzheimer disease: the emerging role of epigenetics	86
Sex and gender in neurodevelopmental conditions	82
Hope for patients with neuromyelitis optica spectrum disorders — from mechanisms to trials	81
White matter injury in infants with intraventricular haemorrhage: mechanisms and therapies	78
Amyloid-β: a potential link between epilepsy and cognitive decline	78
Neurobehavioural comorbidities of epilepsy: towards a network-based precision taxonomy	76
Changing demography and the challenge of dementia in India	75
The role of glial cells in multiple sclerosis disease progression	74
Alzheimer disease in African American individuals: increased incidence or not enough data?	72
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	72
Astrocytes in the initiation and progression of epilepsy	71
Can we learn lessons from the FDA’s approval of aducanumab?	71
Aducanumab and the FDA — where are we now?	71
Bruton tyrosine kinase inhibitors for multiple sclerosis	71
The role of the gut microbiota in multiple sclerosis	70
Identification of clinically relevant biomarkers of epileptogenesis — a strategic roadmap	69
Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies	69
Tau-targeting therapies for Alzheimer disease: current status and future directions	64
A global view of the genetic basis of Alzheimer disease	63
Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease	63
Cluster headache pathophysiology — insights from current and emerging treatments	62
Early-stage Alzheimer disease: getting trial-ready	62
The multiple sclerosis prodrome	61